{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:29:29Z","timestamp":1790911769570,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.ejphar.2008.11.025","type":"journal-article","created":{"date-parts":[[2008,11,22]],"date-time":"2008-11-22T04:27:30Z","timestamp":1227328050000},"page":"355-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dexfenfluramine discontinuous treatment does not worsen hypoxia-induced pulmonary vascular remodeling but activates RhoA\/ROCK pathway: Consequences on pulmonary hypertension"],"prefix":"10.1016","volume":"602","author":[{"given":"Nicolas","family":"Desbuards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Antier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gael Y.","family":"Rochefort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie S.","family":"Apfeldorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Schenck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Hanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Hyvelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2008.11.025_bib1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2008.11.025_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0026-0495(95)90207-4","article-title":"Serotonin and dietary fat intake: effects of dexfenfluramine","volume":"44","author":"Blundell","year":"1995","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2008.11.025_bib3","doi-asserted-by":"crossref","first-page":"H2450","DOI":"10.1152\/ajpheart.00524.2005","article-title":"Doppler tissue imaging in assessment of pulmonary hypertension-induced right ventricle dysfunction","volume":"289","author":"Boissiere","year":"2005","journal-title":"Am. J. Physiol, Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2008.11.025_bib4","doi-asserted-by":"crossref","first-page":"H1023","DOI":"10.1152\/ajpheart.00802.2003","article-title":"Chronic hypoxia induces nonreversible right ventricle dysfunction and dysplasia in rats","volume":"287","author":"Bonnet","year":"2004","journal-title":"Am. J. Physiol, Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2008.11.025_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2008.11.025_bib6","first-page":"H1173","article-title":"Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats","volume":"272","author":"Eddahibi","year":"1997","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2008.11.025_bib7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1164\/ajrccm.157.4.9704095","article-title":"Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia","volume":"157","author":"Eddahibi","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2008.11.025_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/01.RES.84.3.329","article-title":"Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin","volume":"84","author":"Eddahibi","year":"1999","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2008.11.025_bib9","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1172\/JCI8678","article-title":"Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene","volume":"105","author":"Eddahibi","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2008.11.025_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0022-3565(24)29522-7","article-title":"Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats","volume":"297","author":"Eddahibi","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2008.11.025_bib11","doi-asserted-by":"crossref","first-page":"L656","DOI":"10.1152\/ajplung.00090.2003","article-title":"Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase","volume":"287","author":"Fagan","year":"2004","journal-title":"Am. J. Physiol., Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejphar.2008.11.025_bib12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/hrt.2003.029470","article-title":"Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension","volume":"91","author":"Fukumoto","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2008.11.025_bib13","doi-asserted-by":"crossref","first-page":"184S","DOI":"10.1378\/chest.114.3_Supplement.184S","article-title":"Primary pulmonary hypertension: insights into pathogenesis from epidemiology","volume":"114","author":"Galie","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2008.11.025_bib14","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1378\/chest.116.4.921","article-title":"The acute effects of dexfenfluramine on human and porcine pulmonary vascular tone and resistance","volume":"116","author":"Higenbottam","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2008.11.025_bib28","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1161\/CIRCULATIONAHA.105.556704","article-title":"Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction","volume":"112","author":"Hong","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2008.11.025_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1113\/jphysiol.2002.030676","article-title":"Chronic hypoxia causes angiogenesis in addition to remodelling in the adult rat pulmonary circulation","volume":"547","author":"Howell","year":"2003","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejphar.2008.11.025_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/01.RES.0000174287.17953.83","article-title":"Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation","volume":"97","author":"Hyvelin","year":"2005","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2008.11.025_bib17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nm764","article-title":"Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension","volume":"8","author":"Launay","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2008.11.025_bib18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0891-5849(97)00359-6","article-title":"Superoxide as an intermediate signal for serotonin-induced mitogenesis","volume":"24","author":"Lee","year":"1998","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2008.11.025_bib19","first-page":"L282","article-title":"Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion","volume":"277","author":"Lee","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2008.11.025_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6904-2-6","article-title":"Appetite suppressants and valvular heart disease \u2014 a systematic review","volume":"2","author":"Loke","year":"2002","journal-title":"BMC Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.11.025_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-4419-8997-0_9","article-title":"Hypoxia and Rho\/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension","volume":"543","author":"McMurtry","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejphar.2008.11.025_bib22","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1152\/japplphysiol.00500.2002","article-title":"Dexfenfluramine protects against pulmonary hypertension in rats","volume":"93","author":"Mitani","year":"2002","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.ejphar.2008.11.025_bib23","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1164\/rccm.200405-637OC","article-title":"Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension","volume":"171","author":"Nagaoka","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2008.11.025_bib29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0076-6879(07)00415-6","article-title":"Rho kinase-mediated vasoconstriction in rat models of pulmonary hypertension","volume":"439","author":"Oka","year":"2008","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ejphar.2008.11.025_bib24","first-page":"L662","article-title":"Dexfenfluramine increases pulmonary artery smooth muscle intracellular Ca2+, independent of membrane potential","volume":"277","author":"Reeve","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2008.11.025_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejphar.2006.08.050","article-title":"Dexfenfluramine does not worsen but moderates progression of chronic hypoxia-induced pulmonary hypertension","volume":"550","author":"Rochefort","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.11.025_bib26","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1089\/ars.2005.7.1302","article-title":"Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology","volume":"7","author":"Touyz","year":"2005","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.ejphar.2008.11.025_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2165\/00002018-200629070-00003","article-title":"Heart failure induced by non-cardiac drugs","volume":"29","author":"Slordal","year":"2006","journal-title":"Drug Safety"},{"key":"10.1016\/j.ejphar.2008.11.025_bib27","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/01.CIR.94.9.2216","article-title":"Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction","volume":"94","author":"Weir","year":"1996","journal-title":"Circulation"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908011758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908011758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:00:35Z","timestamp":1762142435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299908011758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":30,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0014299908011758"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.11.025","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dexfenfluramine discontinuous treatment does not worsen hypoxia-induced pulmonary vascular remodeling but activates RhoA\/ROCK pathway: Consequences on pulmonary hypertension","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}